Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

NCT02736721 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelogenous Leukemia, Chronic

Interventions

DRUG: Peginterferon alfa-2a

Sponsor

Hoffmann-La Roche